{
  "nctId": "NCT05064800",
  "briefTitle": "PF-07321332/Ritonavir and Ritonavir on Dabigatran Study in Healthy Participants",
  "officialTitle": "A PHASE 1, OPEN-LABEL, 3-TREATMENT, 6-SEQUENCE, 3-PERIOD CROSSOVER STUDY TO ESTIMATE THE EFFECT OF PF-07321332/RITONAVIR AND RITONAVIR ON THE PHARMACOKINETICS OF DABIGATRAN IN HEALTHY PARTICIPANTS",
  "protocolDocument": {
    "nctId": "NCT05064800",
    "filename": "Prot_000.pdf",
    "label": "Study Protocol",
    "date": "2021-08-03",
    "uploadDate": "2022-10-18T11:01",
    "size": 3635436,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT05064800/document/Prot_000.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [
    "PHASE1"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "NON_RANDOMIZED",
  "interventionModel": "CROSSOVER",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 24,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2021-09-21",
    "completionDate": "2021-12-06",
    "primaryCompletionDate": "2021-12-06",
    "firstSubmitDate": "2021-09-01",
    "firstPostDate": "2021-10-01"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Body Mass Index (BMI) of 17.5 to 30.5 kg.m2; and a total body weight \\>50 kg (110 lbs)\n* Female participants must have a negative pregnancy test\n\nExclusion Criteria:\n\n* Positive test for SARS-Co-V2 at the time of screening or Day -1\n* Active pathological bleeding or risk of bleeding\n* Positive urine drug test\n* History of sensitivity to heparin or heparin induced thrombocytopenia\n* Participants who have been vaccinated for COVID-19 in the past 7 days",
    "healthyVolunteers": true,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "60 Years",
    "stdAges": [
      "ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Plasma Dabigatran (Total) PK Parameters (PF-07321332/Ritonavir Co-administered With Dabigatran [Treatment 2]): Maximum Plasma Concentration (Cmax)",
        "description": "Cmax was defined as maximum observed plasma concentration.",
        "timeFrame": "Treatment 1 Day 1 pre-dose, and at 1, 2, 4, 6, 8, 12, 16, 24, 36 and 48 hours post-dose. Treatment 2 Day 2 pre-dose, and at 1, 2, 4, 6, 8, 12, 16, 24, 36 and 48 hours post-dose"
      },
      {
        "measure": "Plasma Dabigatran (Total) PK Parameters (PF-07321332/Ritonavir Co-administered With Dabigatran [Treatment 2]): AUCinf",
        "description": "AUCinf was defined as the area under the plasma concentration-time curve from time 0 extrapolated to infinity",
        "timeFrame": "Treatment 1 Day 1 pre-dose, and at 1, 2, 4, 6, 8, 12, 16, 24, 36 and 48 hours post-dose. Treatment 2 Day 2 pre-dose, and at 1, 2, 4, 6, 8, 12, 16, 24, 36 and 48 hours post-dose"
      },
      {
        "measure": "Plasma Dabigatran (Total) PK Parameters (PF-07321332/Ritonavir Co-administered With Dabigatran [Treatment 2]): AUClast",
        "description": "AUClast was defined as area under the plasma concentration time curve from time 0 to the time of the last measurable concentration.",
        "timeFrame": "Treatment 1 Day 1 pre-dose, and at 1, 2, 4, 6, 8, 12, 16, 24, 36 and 48 hours post-dose. Treatment 2 Day 2 pre-dose, and at 1, 2, 4, 6, 8, 12, 16, 24, 36 and 48 hours post-dose"
      }
    ],
    "secondary": [
      {
        "measure": "Plasma Dabigatran (Total) PK Parameters (Ritonavir Co-administered With Dabigatran [Treatment 3]): Maximum Plasma Concentration (Cmax)",
        "description": "Cmax was defined as maximum observed plasma concentration",
        "timeFrame": "Treatment 1 Day 1 pre-dose, and at 1, 2, 4, 6, 8, 12, 16, 24, 36 and 48 hours post-dose. Treatment 3 Day 2 pre-dose, and at 1, 2, 4, 6, 8, 12, 16, 24, 36 and 48 hours post-dose"
      },
      {
        "measure": "Plasma Dabigatran (Total) PK Parameters (Ritonavir Co-administered With Dabigatran [Treatment 3]): AUCinf",
        "description": "AUCinf was defined as area under the plasma concentration-time curve from time 0 extrapolated to infinity",
        "timeFrame": "Treatment 1 Day 1 pre-dose, and at 1, 2, 4, 6, 8, 12, 16, 24, 36 and 48 hours post-dose. Treatment 3 Day 2 pre-dose, and at 1, 2, 4, 6, 8, 12, 16, 24, 36 and 48 hours post-dose"
      },
      {
        "measure": "Plasma Dabigatran (Total) PK Parameters (Ritonavir Co-administered With Dabigatran [Treatment 3]): AUClast",
        "description": "AUClast was defined as area under the plasma concentration time curve from time 0 to the time of the last measurable concentration.",
        "timeFrame": "Treatment 1 Day 1 pre-dose, and at 1, 2, 4, 6, 8, 12, 16, 24, 36 and 48 hours post-dose. Treatment 3 Day 2 pre-dose, and at 1, 2, 4, 6, 8, 12, 16, 24, 36 and 48 hours post-dose"
      },
      {
        "measure": "Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs , and TEAEs Leading to Participant Discontinuation From Study",
        "description": "An adverse event (AE) was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An serious adverse event (SAE) was defined as an AE: 1. resulting in death, 2. was life-threatening, 3. required inpatient hospitalization or prolongation of existing hospitalization, 4. resulted in persistent disability, 5. was a congenital anomaly/birth defect, or considered to be an important medical event. Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug.",
        "timeFrame": "From Pre-dose on Day 1 to Day 48"
      },
      {
        "measure": "Number of Participants With Laboratory Test Abnormality (Without Regard to Baseline Abnormality)",
        "description": "To determine if there are any clinically significant laboratory abnormalities, the haematological, clinical chemistry (serum) and urinalysis safety tests were assessed against the criteria specified in the sponsor reporting standards. Tests including Ery. Mean Corpuscular Hemoglobin, Eosinophils, Activated Partial Thromboplastin Time, Bilirubin, Fibrinogen, URINE Hemoglobin, Nitrite, and Leukocyte Esterase tests.",
        "timeFrame": "From pre-dose on Day 1 to Day 3"
      },
      {
        "measure": "Number of Participants With Vital Signs of Potential Clinical Concern",
        "description": "Single supine blood pressure and pulse rate tests were assessed against the criteria specified in the sponsor reporting standards.",
        "timeFrame": "From pre-dose on Day 1 to Day 3"
      },
      {
        "measure": "Number of Participants With ECG Values of Potential Clinical Concern",
        "description": "QT interval, QTc, PR, RR, QRS and heart rate tests were assessed against the criteria specified in the sponsor reporting standards.",
        "timeFrame": "From pre-dose on Day 1 to Day 3"
      },
      {
        "measure": "Plasma Dabigatran (Total) PK Parameters (PF-07321332/Ritonavir Co-administered With Dabigatran [Treatment 2]): Time to First Occurrence of Cmax (Tmax)",
        "description": "Tmax was defined as time to first occurrence of Cmax",
        "timeFrame": "Treatment 2 Day 2 pre-dose, and at 1, 2, 4, 6, 8, 12, 16, 24, 36 and 48 hours post-dose"
      },
      {
        "measure": "Plasma Dabigatran (Total) PK Parameters (Ritonavir Co-administered With Dabigatran [Treatment 3]): Tmax",
        "description": "Tmax was defined as time to first occurrence of Cmax.",
        "timeFrame": "Treatment 3 Day 2 pre-dose, and at 1, 2, 4, 6, 8, 12, 16, 24, 36 and 48 hours post-dose"
      },
      {
        "measure": "Plasma Dabigatran (Total) PK Parameters (PF-07321332/Ritonavir Co-administered With Dabigatran [Treatment 2]): Terminal Half-life (t½)",
        "description": "t½ was defined as terminal half-life of Dabigatran (Total) PK Parameters (PF-07321332/ritonavir co-administered with dabigatran.",
        "timeFrame": "Treatment 2 Day 2 pre-dose, and at 1, 2, 4, 6, 8, 12, 16, 24, 36 and 48 hours post-dose"
      },
      {
        "measure": "Plasma Dabigatran (Total) PK Parameters (Ritonavir Co-administered With Dabigatran [Treatment 3]): t½",
        "description": "t½ was defined as terminal half-life of Dabigatran (Total).",
        "timeFrame": "Treatment 3 Day 2 pre-dose, and at 1, 2, 4, 6, 8, 12, 16, 24, 36 and 48 hours post-dose"
      },
      {
        "measure": "Plasma PF-07321332 PK Parameters: Cmax",
        "timeFrame": "Treatment 2 Day 2 pre-dose, and at 1, 2, 4, 6, 8, 12 hours post-dose"
      },
      {
        "measure": "Plasma PF-07321332 PK Parameters: AUCtau",
        "description": "AUCtau was defined as area under the plasma concentration-time profile from time zero to time tau (τ) the dosing interval, where tau=12 hours for twice daily (BID) dosing.",
        "timeFrame": "Treatment 2 Day 2 pre-dose, and at 1, 2, 4, 6, 8, 12 hours post-dose"
      },
      {
        "measure": "Plasma PF-07321332 PK Parameters: t½",
        "description": "t½ was defined as terminal half-life of PF-07321332.",
        "timeFrame": "Treatment 2 Day 2 pre-dose, and at 1, 2, 4, 6, 8, 12 hours post-dose"
      },
      {
        "measure": "Plasma PF-07321332 PK Parameters: Tmax",
        "description": "Tmax was defined as time to first occurrence of Cmax.",
        "timeFrame": "Treatment 2 Day 2 pre-dose, and at 1, 2, 4, 6, 8, 12 hours post-dose"
      },
      {
        "measure": "Plasma PF-07321332 PK Parameters: CL/F",
        "description": "CL/F was defined as apparent clearance of drug from plasma.",
        "timeFrame": "Treatment 2 Day 2 pre-dose, and at 1, 2, 4, 6, 8, 12 hours post-dose"
      },
      {
        "measure": "Plasma PF-07321332 PK Parameters: Vz/F",
        "description": "Vz/F was defined as apparent volume of distribution.",
        "timeFrame": "Treatment 2 Day 2 pre-dose, and at 1, 2, 4, 6, 8, 12 hours post-dose"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 3,
      "secondaryCount": 17,
      "otherCount": 0,
      "totalCount": 20
    },
    "studyDesign": {
      "phases": [
        "PHASE1"
      ],
      "isRandomized": false,
      "isMasked": false,
      "interventionModel": "CROSSOVER"
    },
    "overallComplexityScore": 100,
    "complexityCategory": "Highly Complex"
  },
  "collectionDate": "2025-09-22T02:30:35.863Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}